$RPD

Why is Rapid7 stock rallying today?

Rapid7 shares rose about 5.1% pre-open after the company reported Q2 2026 results that beat expectations, with adjusted EPS of $0.44 vs $0.35 and revenue of $210.9M vs $208.2M. Rapid7 raised full-year adjusted EPS guidance to $1.78–$1.83 and Q3 EPS to $0.44–$0.47, and approved a restructuring plan cutting staff ~12%.

Original reporting
Published Aug 11, 2026, 12:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 1:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$RPD
Bullish
medium confidence
Mentioned
$RPD
Relevance
8/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$RPDBullishMed
01

Why it matters

Rapid7’s Q2 adjusted EPS and revenue beat, plus raised full-year and Q3 EPS guidance, are the immediate drivers. The board-approved workforce reduction and stated path to a 20% non-GAAP operating margin target add credibility to the profitability story, but the article highlights ongoing ARR softness and cautious Q3 net new ARR commentary.

02

Market read

Company-specific earnings and guidance upgrades are likely to drive continued momentum in the stock, with traders watching whether ARR trends stabilize alongside margin improvements.

03

What to watch

Restructuring charges ($10–$11 million) could pressure near-term results, and analyst upgrades were paired with neutral-equivalent ratings due to lingering top-line growth concerns.

Relevance 8/10Novelty 8/10Timing: pre-open today after Aug 10 Q2 earnings and guidance release

Background

The piece frames Rapid7’s move as an earnings-and-guidance-driven repricing during cybersecurity earnings season, against a backdrop of modestly higher major US indexes.

Company-level read

Ticker impact

$RPDBullishMedium confidence
Context

Rapid7 shares rose 5.1% pre-open after Q2 2026 results beat estimates and management raised full-year adjusted EPS guidance to $1.78–$1.83.

Expected impact

Near-term upside bias as investors reprice profitability and margin trajectory, tempered by ongoing ARR decline and cautious Q3 net new ARR outlook.

Evidence & confidence

The article cites specific EPS and revenue beats, explicit guidance increases, and a workforce reduction tied to a 20% non-GAAP operating margin target, which typically supports multiple expansion. However, it also flags continued annual recurring revenue decline and cautious Q3 ARR commentary, limiting conviction.

Market effects

Supports the narrative of improving profitability among managed security and threat detection vendors, potentially lifting sentiment across cybersecurity earnings season.

Limited direct regional spillover; mostly US-focused sentiment given the S&P 500 and Nasdaq context.

Modest global relevance as cybersecurity demand is broadly enterprise-driven, but the catalyst is company-specific.

Counterpoint

The rally may fade if investors focus on the continued year-over-year annual recurring revenue decline and the cautious Q3 net new ARR outlook rather than EPS and margin targets.

Key entities

  • Rapid7

    Cybersecurity company reporting Q2 2026 earnings beat, raising full-year adjusted EPS guidance, and approving a restructuring plan.

  • Stephens

    Raised its price target to $12 from $10 while keeping a neutral-equivalent rating.

  • Scotiabank

    Lifted its price target to $10.15 from $7.00 while maintaining a neutral-equivalent rating.

Related articles

$RPDMedAI 8/10

Expected Sales In Q2 CY2026, Stock Soars

Rapid7 (NASDAQ:RPD) reported Q2 CY2026 revenue of $210.9 million, down 1.5% year on year but 1.4% above estimates. Next-quarter revenue guidance is $209 million, about 0.9% below analysts. Non-GAAP EPS was $0.44, 26.3% above consensus. The stock rose 6.1% to $12.34 after results.

$OFIXMed

These 7 Small Caps Are On Fire In July: Here's Why - ExxonMobil Holdings (NYSE:XOM), Vertex Pharmaceutica

The Russell 2000 stayed near 3,000 with little movement, while seven small-cap stocks gained at least 28% in four sessions. The article cites July surges for Orthofix (OFIX) on CMS reimbursement reversal, REGENXBIO (RGNX) on FDA resubmission alignment and AbbVie milestone, Verastem (VSTM) on short-squeeze setup, ADC Therapeutics (ADCT) rebound, Sable Offshore (SOC) refinancing, Rapid7 (RPD) takeover speculation, and Crinetics (CRNX) surge toward an offer price.

$RPDMedAI 8/10

Rapid7 (RPD) Stock Trades Down, Here Is Why

Rapid7 (NASDAQ: RPD) shares fell 11.3% in the morning after Morgan Stanley downgraded the stock from Equal Weight to Underweight and kept a $9 price target. The firm cited competitive pressure in vulnerability management from AI-focused rivals and said Rapid7 has lagged in exposure management and real-time remediation. RPD is down 26.5% YTD.

$RPDMedAI 8/10

Rapid7 (RPD) Releases Findings of Q1 Threat Landscape Report

Rapid7 (NASDAQ:RPD) released its Q1 2026 Threat Landscape Report on May 21, citing vulnerability exploitation as 38% of incident response cases. The company said AI is speeding attackers’ ability to identify and exploit unpatched systems. Separately, Barclays lowered its price target and kept an Underweight rating after Rapid7’s Q1 results, citing weaker-than-expected Q2 ARR guidance. Rapid7 projects Q2 ARR of about $820M versus $832M in Q1.

$ACCSMed

ACCESS Newswire Inc. (ACCS): Results of Operations and Financial Condition

ACCESS Newswire Inc. (ACCS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 access_ex9901.htm PRESS RELEASE Exhibit 99.1 ACCESS Newswire Reports Second Quarter 2026 Results Average ARR and cashflow from operations continue to increase over PY, as Adjusted EBITDA remains positive · Average ARR for subscriptions per customer at the end of Q2 2026